Iovance Biotherapeutics (IOVA) Competitors

$3.70 +0.08 (+2.21%)

Closing price 05/11/2026 04:00 PM Eastern

Extended Trading

$3.76 +0.06 (+1.62%)

As of 04:06 AM Eastern

IOVA vs. ACLX, MIRM, PTGX, COGT, and BLTE

Should you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Arcellx (ACLX), Mirum Pharmaceuticals (MIRM), Protagonist Therapeutics (PTGX), Cogent Biosciences (COGT), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does Iovance Biotherapeutics compare to Arcellx?

Iovance Biotherapeutics (NASDAQ:IOVA) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

In the previous week, Iovance Biotherapeutics had 16 more articles in the media than Arcellx. MarketBeat recorded 18 mentions for Iovance Biotherapeutics and 2 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Iovance Biotherapeutics' score of 0.10 indicating that Arcellx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcellx	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Iovance Biotherapeutics presently has a consensus price target of $8.43, indicating a potential upside of 127.80%. Arcellx has a consensus price target of $111.87, indicating a potential downside of 2.78%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Iovance Biotherapeutics is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11

Iovance Biotherapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Arcellx has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Iovance Biotherapeutics has a net margin of -123.92% compared to Arcellx's net margin of -1,027.26%. Iovance Biotherapeutics' return on equity of -50.17% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Arcellx	-1,027.26%	-55.42%	-36.24%

Arcellx has lower revenue, but higher earnings than Iovance Biotherapeutics. Arcellx is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.27	-$390.98M	-$0.95	N/A
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Iovance Biotherapeutics beats Arcellx on 10 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Mirum Pharmaceuticals?

Iovance Biotherapeutics (NASDAQ:IOVA) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Iovance Biotherapeutics presently has a consensus price target of $8.43, indicating a potential upside of 127.80%. Mirum Pharmaceuticals has a consensus price target of $136.42, indicating a potential upside of 28.49%. Given Iovance Biotherapeutics' higher probable upside, research analysts plainly believe Iovance Biotherapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has higher revenue and earnings than Iovance Biotherapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.27	-$390.98M	-$0.95	N/A
Mirum Pharmaceuticals	$521.31M	12.42	-$23.36M	-$13.61	N/A

Iovance Biotherapeutics has a net margin of -123.92% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Iovance Biotherapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 15 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 33 mentions for Mirum Pharmaceuticals and 18 mentions for Iovance Biotherapeutics. Mirum Pharmaceuticals' average media sentiment score of 0.40 beat Iovance Biotherapeutics' score of 0.10 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	7 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Mirum Pharmaceuticals beats Iovance Biotherapeutics on 11 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Protagonist Therapeutics currently has a consensus price target of $113.69, indicating a potential upside of 9.85%. Iovance Biotherapeutics has a consensus price target of $8.43, indicating a potential upside of 127.80%. Given Iovance Biotherapeutics' higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Protagonist Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	144.63	-$130.15M	-$1.81	N/A
Iovance Biotherapeutics	$263.50M	6.27	-$390.98M	-$0.95	N/A

Iovance Biotherapeutics has a net margin of -123.92% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Protagonist Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

In the previous week, Protagonist Therapeutics had 5 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 23 mentions for Protagonist Therapeutics and 18 mentions for Iovance Biotherapeutics. Protagonist Therapeutics' average media sentiment score of 0.36 beat Iovance Biotherapeutics' score of 0.10 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Protagonist Therapeutics beats Iovance Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

In the previous week, Iovance Biotherapeutics had 9 more articles in the media than Cogent Biosciences. MarketBeat recorded 18 mentions for Iovance Biotherapeutics and 9 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.71 beat Iovance Biotherapeutics' score of 0.10 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cogent Biosciences has higher earnings, but lower revenue than Iovance Biotherapeutics. Cogent Biosciences is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Iovance Biotherapeutics	$263.50M	6.27	-$390.98M	-$0.95	N/A

77.0% of Iovance Biotherapeutics shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cogent Biosciences currently has a consensus price target of $43.73, indicating a potential upside of 28.23%. Iovance Biotherapeutics has a consensus price target of $8.43, indicating a potential upside of 127.80%. Given Iovance Biotherapeutics' higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Cogent Biosciences has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Cogent Biosciences has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Summary

Iovance Biotherapeutics beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Belite Bio has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Belite Bio's return on equity of -19.49% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-19.49%	-19.05%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Belite Bio currently has a consensus price target of $202.33, indicating a potential upside of 33.14%. Iovance Biotherapeutics has a consensus price target of $8.43, indicating a potential upside of 127.80%. Given Iovance Biotherapeutics' higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

In the previous week, Iovance Biotherapeutics had 6 more articles in the media than Belite Bio. MarketBeat recorded 18 mentions for Iovance Biotherapeutics and 12 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.47 beat Iovance Biotherapeutics' score of 0.10 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Belite Bio has a beta of -1.19, meaning that its share price is 219% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Belite Bio has higher earnings, but lower revenue than Iovance Biotherapeutics. Belite Bio is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.30	N/A
Iovance Biotherapeutics	$263.50M	6.27	-$390.98M	-$0.95	N/A

Summary

Belite Bio beats Iovance Biotherapeutics on 8 of the 15 factors compared between the two stocks.

Get Iovance Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IOVA vs. The Competition

Export

Metric	Iovance Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.62B	$3.39B	$6.24B	$12.31B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-3.89	15.06	20.63	25.69
Price / Sales	6.27	306.19	551.52	76.29
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	2.10	6.94	9.67	6.74
Net Income	-$390.98M	$24.11M	$3.54B	$333.18M
7 Day Performance	-7.04%	-0.90%	-0.25%	0.42%
1 Month Performance	N/A	4.62%	6.26%	8.99%
1 Year Performance	91.71%	72.73%	39.15%	37.93%

Iovance Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IOVA Iovance Biotherapeutics	2.7525 of 5 stars	$3.70 +2.2%	$8.43 +127.8%	+111.4%	$1.62B	$263.50M	N/A	500	Earnings Report
ACLX Arcellx	2.6245 of 5 stars	$115.07 flat	$111.87 -2.8%	+99.2%	$6.73B	$22.29M	N/A	80	High Trading Volume
MIRM Mirum Pharmaceuticals	2.6974 of 5 stars	$105.79 +9.6%	$123.83 +17.1%	+139.8%	$6.45B	$521.31M	N/A	140	Earnings Report Analyst Downgrade Analyst Revision High Trading Volume
PTGX Protagonist Therapeutics	2.1351 of 5 stars	$99.52 +1.2%	$108.15 +8.7%	+140.5%	$6.40B	$46.02M	N/A	120	Positive News Earnings Report Analyst Upgrade Insider Trade
COGT Cogent Biosciences	3.3469 of 5 stars	$36.73 +0.3%	$43.45 +18.3%	+604.5%	$6.27B	N/A	N/A	80	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IOVA) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. ACLX, MIRM, PTGX, COGT, and BLTE

How does Iovance Biotherapeutics compare to Arcellx?

Summary

How does Iovance Biotherapeutics compare to Mirum Pharmaceuticals?

Summary

How does Iovance Biotherapeutics compare to Protagonist Therapeutics?

Summary

How does Iovance Biotherapeutics compare to Cogent Biosciences?

Summary

How does Iovance Biotherapeutics compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. ACLX, MIRM, PTGX, COGT, and BLTE

How does Iovance Biotherapeutics compare to Arcellx?

Does the media favor IOVA or ACLX?

Do analysts recommend IOVA or ACLX?

Which has more volatility and risk, IOVA or ACLX?

Is IOVA or ACLX more profitable?

Which has preferable earnings & valuation, IOVA or ACLX?

Do insiders and institutionals believe in IOVA or ACLX?

Summary

How does Iovance Biotherapeutics compare to Mirum Pharmaceuticals?

Do insiders and institutionals believe in IOVA or MIRM?

Do analysts recommend IOVA or MIRM?

Which has preferable earnings & valuation, IOVA or MIRM?

Is IOVA or MIRM more profitable?

Which has more volatility and risk, IOVA or MIRM?

Does the media favor IOVA or MIRM?

Summary

How does Iovance Biotherapeutics compare to Protagonist Therapeutics?

Do institutionals and insiders believe in PTGX or IOVA?

Do analysts prefer PTGX or IOVA?

Which has higher earnings & valuation, PTGX or IOVA?

Is PTGX or IOVA more profitable?

Which has more risk & volatility, PTGX or IOVA?

Does the media refer more to PTGX or IOVA?

Summary

How does Iovance Biotherapeutics compare to Cogent Biosciences?

Does the media refer more to COGT or IOVA?

Which has stronger valuation and earnings, COGT or IOVA?

Do institutionals and insiders believe in COGT or IOVA?

Do analysts rate COGT or IOVA?

Is COGT or IOVA more profitable?

Which has more volatility and risk, COGT or IOVA?

Summary

How does Iovance Biotherapeutics compare to Belite Bio?

Is BLTE or IOVA more profitable?

Do analysts rate BLTE or IOVA?

Does the media refer more to BLTE or IOVA?

Do institutionals and insiders believe in BLTE or IOVA?

Which has more volatility and risk, BLTE or IOVA?

Which has stronger valuation and earnings, BLTE or IOVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools